EZH2 and neoplasm: Consistently, the tumor sizes in the zebrafish HCC primary tumors (KRASG12V+) decreased with Roblitinib treatment, while in the zebrafish HCC primary tumors containing ectopic EZH2 expression, Roblitinib failed to inhibit the HCC cell growth (Fig. 2F and G).